Search results
Minnesota Justices Question State’s Taxation of Drug Rebates
Bloomberg Law· 6 days agoThree Minnesota Supreme Court justices at arguments Monday seemed likely to agree with a wholesale drug distributor that the state’s $500,000 tax bill improperly characterized ...
Letter to the editor: I worry about the government setting prescription prices
Summit Daily News· 6 hours agoAs someone who relies on prescription medications, I fully support efforts to increase access and...
Viking Therapeutics Stock Falls After Drug Study Report
Investor's Business Daily· 5 days agoThe company tested its drug, dubbed VK2809, in patients with nonalcoholic steatohepatitis, or NASH....
DC Circuit Affirms 340B Program Does Not Prohibit All Drug Manufacturer Distribution Restrictions |...
JD Supra· 7 days agoIn what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service ...
To protect patients, Congress must pass comprehensive PBM reform
Las Vegas Sun· 3 days agoNo one should have to struggle to access the prescription treatments they need to live a healthier,...
Viking's MASH drug scored where Madrigal's didn't, but shares fall on lack of direction
FierceBiotech· 5 days agoViking Therapeutics is pulling up some extra long boats full of reasons the metabolic...
JD Supra: Better Health Care Newsletter
JD Supra· 3 days agoFederal officials have capped the cost of insulin at $35 a month. For now, that gives relief only to patients 65 and older covered by Medicare. Big Pharma in recent years has flouted that charitable intent.
AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters via Yahoo News· 3 days agoAbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine...
Our opinion: State must pursue PBM reform
Warren Times Observer· 7 days agoIt’s easy for our eyes to glass over when we hear state legislators are discussing legislation to reform the contract process between pharmacies and drug companies. Known ...
Medicare Part D Plans Poorly Cover Adalimumab Biosimilars
Medscape· 4 days agoThis narrow coverage limits the cost-saving potential of these biosimilar competitors, expert said.
